. Author manuscript; available in PMC: 2020 Nov 29.

Published in final edited form as: Surg Oncol Clin N Am. 2020 Apr;29(2):293–316. doi: 10.1016/j.soc.2019.11.004

Table 4 –

Randomized clinical trials with interferons

Trial	Treatment arms	Number of patients	Results
RCT Kolby L et al 2002⁷³	IFNα+ Octreotide vs Octreotide	68 metastatic SBNETs	No difference in 5-year OS. 56.8% vs 36.6%. IFNα treated patients with reduced risk of tumor progression (p=0.008)
RCT Arnold R et al 2005⁷⁴	IFN α+ Octreotide vs Octreotide	105 metastatic GEPNETs	Long term OS similar at 35 months for monotherapy and 51 months for combination. (HR1.19,95%CI [0.67–2.13; p=0.55). PFS similar
RCT Faiss S et al⁷⁵	Lanreotide+ IFNα vs Lanreotide vs IFNα	80 therapy naïve metastatic GEPNETs	No statistically significant difference in rates of partial remission, stable disease or tumor progression in all 3 arms.
RCT open label Yao et al 2017⁷⁶	Octreotide+ Bevacizumab vs Octreotide +IFN-α−2b	427 advanced grade 1 and 2 NETs	No difference in PFS 16.6months vs 15.4months (HR,0.93;95%CI,0.73–1.18, p=0.55)